All News
Filter News
Found 73,940 articles
-
Adial Pharmaceuticals and iRemedy Partner to Sell COVID-19 Antibody Test Kits to U.S. Medical Providers and Commence Sales
9/22/2020
Adial Pharmaceuticals, Inc.today announced that the two companies have commenced sales of FaStep COVID-19 IgG/IgM rapid antibody test kits to healthcare providers and hospitals through the iRemedy network and ecommerce platform.
-
Aphex BioCleanse Systems Announces CMW Media as Strategic Communications Firm
9/22/2020
Aphex BioCleanse Systems, Inc. (OTC: SNST) ("Aphex" or "the Company"), a sanitization solutions company focused on the development and distribution of chemical-free, water-based sanitization and disinfection products, announced today that the Company has appointed CMW Media, a creative and public relations agency specializing in emerging markets, as its strategic communications firm.
-
Oxford Immunotec Joins Forces with Public Health England (PHE) in a Large Clinical Trial Utilizing T-SPOT® Discovery™ SARS-CoV-2 Test
9/22/2020
Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today announced that it has entered into an extensive research collaboration with Public Health England (PHE), an executive agency of the UK’s Department for Health and Social Care (DHSC). As part of this, PHE has launched the ‘Evaluating Detection of SARS-CoV-2 antibodies using home test kits’ study (EDSAB-HOME
-
AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Proprietary Compounds and Methods Targeting Tumor Metastasis Through QSOX1
9/22/2020
AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that the United States Patent and Trademark Office (USPTO) has issued the Company a new Notice of Allowance for a patent (Application No. 15/748,784) on anti-neoplastic compounds and methods targeting Quiescin Sulfhydryl Oxidase 1 (QSOX1), an enzyme impor
-
Precipio Launches its Proprietary HemeScreen™ AML (Acute Myeloid Leukemia) Molecular PanelPanel of clinically critical genes can yield same-day results outperforming major competitors
9/22/2020
- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announced today that it has launched its HemeScreen™ AML (Acute Myeloid Leukemia) panel both clinically in its CLIA laboratory, and as part of its HemeScreen product offering. This new panel expands the HemeScreen offering for reference laboratories and physician office laboratories, enabling them to provide improved patient care through faster turnaround time. Mo
-
XIFIN Executives Expect 15% Increase in Fall COVID-19 Testing Volumes; Seeing Regional Labs Pick Up Overflow from Larger, National Players
9/22/2020
COVID-19 has impacted diagnostic volumes, mix and reimbursement for a variety of diagnostic providers.
-
ViralClear Expands Ongoing Phase 2 Trial Size for its Oral Anti-Viral for the Treatment of COVID-19, Expands Trial Locations and Appoints Contract Manufacturing Organization to Manufacture Phase 3 Supplies of Merimepodib Oral Solution
9/22/2020
Size of ongoing Phase 2 trial of merimepodib in combination with remdesivir increased from 40 to 80 subjects, with focus on hospitalized patients requiring non-invasive ventilation/high flow oxygen devices Added 2 new Principal Investigators for the ongoing Phase 2 trial expanding the total number of locations to 10 Contract Manufacturing Organization (CMO) appointed to manufacture Phase 3 supplies of merimepodib oral solution Me
-
Geneva Biotech Announces SARS-CoV-2 Antiviral Pipeline Based on Ground-Breaking Discovery Published in Science Magazine
9/22/2020
Geneva Biotech today announced a SARS-CoV-2 therapeutics platform, based on a ground-breaking discovery that revealed mechanisms driving the high infectivity, broad tissue tropism and severe pathology of the virus that causes COVID-19.
-
Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine
9/22/2020
Today, Sanofi and GSK announce the signing of agreements with the Government of Canada for the supply of up to 72 million doses of an adjuvanted COVID-19 vaccine, beginning in 2021.
-
Government of Canada signs new agreements to secure additional vaccine candidate and treatment for COVID-19
9/22/2020
The Government of Canada is protecting the health and safety of all Canadians, while ensuring a safe and sustainable economic recovery.
-
ProMIS Neurosciences to develop multivalent vaccine for Alzheimer’s diseasePotential vaccine to incorporate ProMIS proprietary peptide antigens; early in vivo preclinical data demonstrate neuronal protection and improvement in cognitive deficits
9/22/2020
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today initiation of a program to construct and test a multivalent peptide vaccine for Alzheimer’s disease (AD). The critical first steps in vaccine development will be carried out by VIDO-Inte
-
Lantern Pharma Announces Collaboration and Research Agreement with Fox Chase Cancer Center Focused on Advancing the Development of LP-184 in Pancreatic Cancer
9/22/2020
Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR ® artificial intelligence ("A.I.") platform to improve drug discovery & development and identify patients who will benefit from its targeted oncology therapeutics, today announced a collaboration and research agreement with Fox Chase Cancer
-
Canada Exercises Increased Option for 20 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)
9/22/2020
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the Canadian Government has increased its confirmed order commitment to 20 million doses of Moderna’s vaccine candidate against COVID-19, mRNA-1273.
-
Microbix Presenting COVID-19 Product Results to IndustryAbstract Reports Multi-Platform Utility of IVD SARS CoV-2 Lab Workflow Control
9/22/2020
Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix ® ), an award-winning life sciences innovator and exporter, announces it is has been invited to present about the performance of its COVID-19 in-vitro diagnostics (IVD) quality assessment products at “ECCVID,” a virtual conference on Coronavirus disease organized by the European Society for Clinical Microbiology and Infectious Diseases (ESCMID), taking place September 23-25, 2020
-
Algernon Announces 50% Enrollment in Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19
9/22/2020
Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has now enrolled 75 patients, which is 50% of its enrollment target, for its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19.
-
Applied UV, Inc. Subsidiary, SteriLumen, Inc., Announces Receipt of Purchase Order for Airocide(TM) Air Quality-Improvement(TM) System from Dubai Creek Golf & Yacht Club Resort
9/22/2020
Applied UV, Inc. announced that its subsidiary, SteriLumen, Inc., together with its distribution partner for the United Arab Emirates, has received a purchase order for the Airocide™ Air Quality-Improvement™ System line of patented, air purification technologies for initial installation in several public space venues at the Dubai Creek Golf & Yacht Club Resort, Dubai UAE.
-
Sinovac Commences Phase III Clinical Trials for COVID-19 Vaccine Candidate in Turkey
9/22/2020
Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that it has recently commenced phase III clinical trials for its inactivated COVID-19 vaccine candidate developed by Sinovac Life Sciences (Sinovac LS), or “CoronaVac,” in Turkey. T
-
Neogen reports first quarter 2021 results
9/22/2020
Neogen Corporation announced that revenues for the first quarter of its 2021 fiscal year, which ended Aug. 31, were $109,325,000, an 8% increase compared to the previous year's first quarter revenues of $101,424,000.
-
Israeli Pain Monitoring Startup Medasense Raises $18M in Series C Round
9/22/2020
Medasense Biometrics Ltd., developer of the NOL technology for pain-response monitoring, today announced that it has raised $18M in a series C round, from Sabadell Asabys venture capital firm (Asabys Partners, Spain), Israeli family offices and returning investors Baxter Ventures, Olive Tree Ventures and LGL Capital.
-
As Pandemic Continues to Spread, ARCpoint Labs of North San Diego Offers the Most Comprehensive Test Menu Available for COVID-19
9/22/2020
ARCpoint Labs offers free Webinar on Sept. 30, 2020 to help identify proper tests, safe ways to return to work and school.